Patent · US Active

Predictive value of nuclear excision repair genes for cancer survival

US8580498B2 · kind B2 · utility

0Cited by

5References

17Claims

0Family size

Assignee

University of South Florida · US

Inventors

George Simon · Livermore, US
Gerold Bepler · Tampa, US

Key dates

Filing date	Feb 14, 2011
Grant date	Nov 12, 2013
Priority date	—
Expiry date	Oct 22, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Patients who have their cancer surgically removed are at risk for recurrence, even though currently free of disease. Lung cancer patients with higher activity of a nuclear excision repair gene called ERCC1 were at a lower risk for recurrence than patients with lower activity of ERCC1. Hence, it is possible to predict which patients are at a higher risk for recurrence after resection. This information can be used to design treatment strategies for patients determined to be at a higher risk for recurrence. Additionally, patients who are lower risk for recurrence can be saved the morbidity of further treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.